

Ind-Swift Laboratories Limited

(A Recognised Export House)



Ref: ISLL:CH:2023

Date: 29th November, 2023

The President Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai 400 001 The Vice President, Listing Compliance Department, National Stock Exchange of India Limited, Exchange Plaza, 5th Floor Plot No. C/2, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai 400 051

ISIN: INE915B01019, INE915B07024 BSE Scrip Code: 532305, 957989

NSE Symbol: INDSWFTLAB

SUBJECT: INTIMATION OF PRESS RELEASE

Ref: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulation").

We are enclosing herewith a press release dated November 29, 2023 titled 'Ind-Swift Laboratories Limited collaborates with CSIR-IMTECH for Development of Biotransformation Process (Enzymatic Process)' being issued by the Company.

You are requested to kindly take the same on record.

Thanking you,

For IND-SWIFT LABORATORIES LTD.

PARDEEP VERMA
VP-CORPORATE AFFAIRS
COMPANY SECRETARY



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office: S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101 Phones: ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294 E-mail: info@indswiftlabs.com Website: www.indswiftlabs.com CIN No. L24232CH1995PLC015553



IND-SWIFT LABORATORIES LIMITED COLLABORATES WITH CSIR-IMTECH FOR DEVELOPMENT OF BIOTRANSFORMATION PROCESS (ENZYMATIC PROCESS)



Pharma Major, Ind-Swift Laboratories Limited has collaborated with The Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology (IMTECH), a premier microbial institute under the aegis of the Ministry of Science and Technology, Government of India, for development of Biotransformation Process (Enzymatic Process) for its products.

The agreement between Ind-Swift and CSIR-IMTECH will enable scientists from both the organizations to work closely on development of Biotransformation process (Enzymatic Process) for its products. For this project, scientists at IMTECH will utilize their expertise and scientific know how in microbiology while Ind-Swift team will provide its expertise in process chemistry & pharmaceutical drug development's analytical resources.

The Technical teams of CSIR-IMTECH headed by Dr. Sanjeev Khosla, Director CSIR-IMTECH, Dr. Mani Shankar Bhattacharya, Principal Scientists, CSIR-IMTECH and Ind-Swift Laboratories Limited headed by its Chairman and Managing Director, Sh. N.R. Munjal, CEO Sh. Sunil Deshmukh, Dr Ashok Prasad, Head-R&D met at Chandigarh today and exchanged project agreement.

Speaking on the occasion Sh. N.R. Munjal, Chairman and Managing Director Ind-Swift Laboratories expressed that "The field of biotransformation process (Enzymatic Process) is an alternative to traditional chemical processes. This collaboration presents a unique opportunity to enhance our capabilities, drive innovation, and optimize production processes. This approach aligns with the growing demand for eco-friendly and efficient manufacturing in the pharmaceutical sector."

Sh. Sunil Deshmukh, CEO of Ind-Swift Laboratories Limited emphasized the importance of Public Private Partnership (PPP) collaboration as the need of hour to bring out scientific and technical





Ind-Swift Laboratories Limited

(A Recognised Export House)



excellence in pharmaceutical sector of India.

CSIR-IMTECH is a national centre for excellence in microbial sciences and was established in 1984 under the aegis of CSIR. IMTECH's vision and mission are to create a translational ecosystem strengthened by fundamental discoveries and to address unmet and industrial needs with state -of-the art processes and platforms.

Ind-Swift Laboratories Limited Headquartered in Chandigarh, India is a global manufacturer of APIs and its Intermediates.

